| Acne |
No |
| Active substance |
Ticagrelor |
| Also known as |
AZD6140 |
| Aromatization |
No |
| Blood pressure |
Can cause transient increase |
| Chemical name |
(1S,2S,3R,5R)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Dosage (medical) |
Typically 90 mg twice daily |
| Dosage (sports) |
Not applicable |
| Effects |
Reduces the rate of stent thrombosis in patients who are at risk, decreases myocardial infarction |
| Formula |
C23H28F2N6O4S |
| Half-life |
Approximately 7 to 8.5 hours |
| HBR |
No |
| Hepatotoxicity |
No |
| Lab Test |
Not specific, may monitor platelet function tests |
| Main action |
Platelet aggregation inhibitor |
| Side effects |
Bleeding, dyspnea, headache, cough, hypertension, nausea |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Substance class |
Antiplatelet agent |
| Trade name |
Brilinta, Brilique, Possia |
| Use in sports |
Not typically used in sports |
| WAREHOUSE |
International Warehouse 2 |
| Water Retention |
No |
| Manufacturer |
AstraZeneca |
